This compound is primarily investigated for its potential in cancer therapy, particularly in targeting and inhibiting the CXCR4 receptor, which is involved in tumor growth, metastasis, and angiogenesis. It has shown promise in preclinical studies for treating hematologic malignancies, such as acute myeloid leukemia (AML) and multiple myeloma, by disrupting the interaction between cancer cells and the bone marrow microenvironment. Additionally, it is being explored as a mobilizing agent for hematopoietic stem cells in stem cell transplantation, enhancing the collection of stem cells for therapeutic use. Its ability to modulate immune responses also makes it a candidate for combination therapies with immunotherapies or chemotherapy to improve treatment outcomes.